Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Scancell Holdings Share Price
  4. Scancell Holdings Share Regulatory News
  5. Appointment of Broker

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Scancell Holdings Information

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 9.50
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 1.50 (15.789%)
Open: 10.25
High: 10.40
Low: 10.00
Prev. Close: 10.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Broker

6 Sep 2010 07:00

6 September 2010 Scancell Holdings Plc Appointment of Broker The Board of Scancell Holdings Plc, (AIM: SCLP), the developer of therapeuticcancer vaccines, announce the appointment of Matrix Corporate Capital LLP asjoint broker with immediate effect.

For further information contact:

Scancell Holdings Plc +44 (0)207 245 1100 Professor Lindy Durrant Hansard Communications +44 (0)207 245 1100 John Bick/Kirsty Corcoran

Zeus Capital - Nominated Adviser/Joint Broker +44 (0)161 831 1512 Ross Andrews/Tom Rowley

Matrix Corporate Capital LLP - Joint Broker +44 (0)20 3206 7340

Robert Naylor/Stephen Waterman

vendor
123456789
Date   Source Headline
21st Feb 20239:05 amRNSSecond Price Monitoring Extn
21st Feb 20239:00 amRNSPrice Monitoring Extension
21st Feb 20237:00 amRNSEncouraging early efficacy data from ModiFY trial
13th Feb 20237:00 amRNSPositive response in COVIDITY trial
8th Feb 20237:00 amRNSIssue of Equity
1st Feb 20237:00 amRNSDr Jean-Michel Cosséry appointed as Chairman
25th Jan 20237:00 amRNSInterim Results
18th Jan 20237:00 amRNSNotice of Interim Results
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20223:18 pmRNSResult of Annual General Meeting
7th Nov 20227:00 amRNSLicenses Vaccitech technology to advance Modi-2
31st Oct 20227:00 amRNSFirst patient dosed in expansion phase of ModiFY
28th Oct 20223:00 pmRNSNotice of AGM
28th Oct 20227:00 amRNSResults for the year ended 30 April 2022
26th Oct 20227:00 amRNSDirectorate Changes
25th Oct 20224:42 pmRNSSecond Price Monitoring Extn
25th Oct 20224:37 pmRNSPrice Monitoring Extension
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 202211:05 amRNSSecond Price Monitoring Extn
25th Oct 202211:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSSigns Commercial License Agreement with Genmab
13th Oct 20227:00 amRNSChange of Nominated Adviser
28th Sep 202212:31 pmRNSHolding(s) in Company
23rd Sep 20227:00 amRNSPreclinical data at the EuroMAbNet Annual Meeting
23rd Sep 20227:00 amRNSPreclinical data at the EuroMAbNet Annual Meeting
6th Sep 202212:54 pmRNSChange of Registered Office
16th Aug 20222:00 pmRNSFirst patient dosed in Cohort 2 of the ModiFY
23rd Jun 20227:00 amRNSScancell to produce TCB antibodies
15th Jun 20222:06 pmRNSSecond Price Monitoring Extn
15th Jun 20222:00 pmRNSPrice Monitoring Extension
15th Jun 20227:00 amRNSPhase 2 SCOPE trial of SCIB1 vaccine expanded
13th Jun 20227:00 amRNSFirst patient dosed in Modi-1 Phase 1 trial
12th Apr 20223:47 pmRNSChange of Registered Holder of Shares
11th Apr 20222:06 pmRNSSecond Price Monitoring Extn
11th Apr 20222:00 pmRNSPrice Monitoring Extension
11th Apr 202211:05 amRNSSecond Price Monitoring Extn
11th Apr 202211:00 amRNSPrice Monitoring Extension
11th Apr 20227:00 amRNSModi-1 Phase 1/2 trial open for recruitment
29th Mar 20227:00 amRNSUpdate on COVIDITY clinical trial
17th Mar 20227:00 amRNSScancell progresses its new anti-glycan mAb
3rd Mar 20229:55 amRNSDirector Dealing
31st Jan 20227:00 amRNSUpdate on COVIDITY Phase 1 clinical trial
26th Jan 20227:00 amRNSInterim Results for the 6 months ended 31 Oct 2021
22nd Dec 20219:45 amRNSNotice of Interim Results
13th Dec 20214:41 pmRNSSecond Price Monitoring Extn
13th Dec 20214:36 pmRNSPrice Monitoring Extension
23rd Nov 20213:58 pmRNSResult of AGM
19th Nov 20217:00 amRNSFirst patient dosed in SCIB1 Phase 2 trial
123456789

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.